GLP-1 RAs and SGLT2-Is to Lower Glucose and Reduce the Risk of Cardiovascular and Diabetic Kidney Disease.
GLP-1 受體激動劑和 SGLT2 抑制劑降低血糖並減少心血管疾病及糖尿病腎病的風險。
J Am Board Fam Med 2024-08-14
Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes.
將 GLP-1 RAs 和 SGLT2 抑制劑作為第一選擇管理第2型糖尿病心血管代謝風險。
Curr Atheroscler Rep 2023-01-29
HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity.
GLP-1RAs 如何在管理T2DM的指引中帶來範式轉變:通往葡萄糖心臟中心的道路。
Indian Heart J 2023-03-08
The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists.
第2型糖尿病管理的演變:使用SGLT-2抑制劑和GLP-1受體激動劑進行血糖控制及更多。
J Osteopath Med 2024-02-26
A New Hope on the Horizon for Kidney and Cardiovascular Protection with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Mineralocorticoid Receptor Antagonists in Type 2 Diabetic and Chronic Kidney Disease Patients.
SGLT2抑制劑、GLP-1受體激動劑和礦質皮質激素受體拮抗劑在2型糖尿病和慢性腎臟病患者中對腎臟和心血管保護帶來新希望。
Metab Syndr Relat Disord 2024-04-15
Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes: an update.
糖尿病患者心血管結果的藥物降糖效應更新。
Expert Opin Drug Metab Toxicol 2024-04-25
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
SGLT2 抑制劑與 GLP-1 受體激動劑在 2 型糖尿病中的腎臟與心血管效果比較。
J Am Coll Cardiol 2024-08-14